Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.51 |
| ▸ | CTSK | P43235 | 6/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47004 | 1.00 | FOLH1 (0.53) | FOLH1ITGB3ITGA2BCTSKCTSS | |
| SCHEMBL376450 | 1.00 | FOLH1 (0.53) | FOLH1ITGB3ITGA2BCTSKCTSS | |
| Hydrochloric Acid SCHEMBL28376761 | 0.98 | FOLH1 (0.51) | FOLH1ITGB3ITGA2BCTSKCTSS | |
| SCHEMBL6751878 | 0.98 | FOLH1 (0.51) | FOLH1ITGB3ITGA2BCTSKCTSS | |
| Hydrochloric Acid SCHEMBL919653 | 0.98 | FOLH1 (0.51) | FOLH1ITGB3ITGA2BCTSKCTSS | |
| Hydrochloric Acid SCHEMBL1711148 | 0.98 | FOLH1 (0.51) | FOLH1ITGB3ITGA2BCTSKCTSS | |
| SCHEMBL30395713 | 0.98 | FOLH1 (0.51) | FOLH1ITGB3ITGA2BCTSKCTSS | |
| Acetic Acid SCHEMBL15812253 | 0.97 | FOLH1 (0.50) | FOLH1ITGB3ITGA2BCTSKCTSS | |
| SCHEMBL205184 | 0.95 | CTSK (0.51) | FOLH1ITGB3ITGA2BCTSKCTSS | |
| SCHEMBL1487792 | 0.95 | CTSK (0.51) | FOLH1ITGB3ITGA2BCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115372341-B | Bioluminescence detection system of bacterial cell wall neopeptidoglycan constructed by D-lysine derivative and application method | 西北工业大学深圳研究院 | 2025-04-25 | — | — | CN | claimed |
| CN-119330951-A | Near infrared fluorescent probe for targeting gram-positive bacteria based on bacterial parietal peptidoglycan synthesis and preparation method and application thereof | 华东理工大学 | 2025-01-21 | — | — | CN | claimed |
| CN-119101187-A | Antibacterial peptide and application thereof | 北京化工大学 | 2024-12-10 | — | — | CN | claimed |
| CN-112023040-B | Derivative of antineoplastic photosensitizer ALA hybrid 3-hydroxypyridine-4H-ketone and preparation method and application thereof | 浙江工业大学 | 2023-03-31 | — | — | CN | claimed |
| CN-113880849-B | Chiral lysine modified zinc phthalocyanine and preparation method and application thereof | 南京师范大学 | 2022-12-16 | — | — | CN | claimed |
| CN-115372341-A | Bioluminescence detection system of bacterial cell wall nascent peptidoglycan constructed by D-lysine derivative and application method | 西北工业大学深圳研究院 | 2022-11-22 | — | — | CN | claimed |
| CN-113880849-A | Chiral lysine modified zinc phthalocyanine and preparation method and application thereof | 南京师范大学 | 2022-01-04 | — | — | CN | claimed |
| US-12503455-B2 | Nucleic acid-binding photoprobes and uses thereof | ARRAKIS THERAPEUTICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| WO-2025132943-A1 | DECAHYDROQUINOLINES AS DNA POLYMERASE THETA INHIBITORS | BREAKPOINT THERAPEUTICS GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| CN-120202243-A | Thermosetting resin composition, cured film, substrate, and electronic component | 捷恩智株式会社 | 2025-06-24 | — | — | CN | disclosed |
| US-20250197869-A1 | Ribosome-Mediated Incorporation of Peptides and Peptidomimetics | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2025111578-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | OLIX US, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20250145577-A1 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | TRANSLATE BIO INC (US) | 2025-05-08 | — | — | US | disclosed |
| EP-1896409-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS USEFUL FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| US-20080025915-A1 | Technetium-And Rhenium-Bis (Heteroaryl) Complexes, And Methods Of Use Thereof | CITIZENS BANK, N.A. | 2008-01-31 | — | — | US | disclosed |
| WO-2007126358-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSOR TION INHIBITOR ACTIVIT. | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | disclosed |
| WO-2006137795-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS USEFUL FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| EP-1699759-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005061452-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| EP-0041243-B1 | NONAPEPTIDE, PROCESS FOR ITS PREPARATION, COMPOSITION CONTAINING IT AND ITS USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503455-B2 | Nucleic acid-binding photoprobes and uses thereof | NSUN3, NSUN2, TARBP1 | FOLH1 601/4885ITGB3 3566/4885ITGA2B 2862/4885 |
| US-20080025915-A1 | Technetium-And Rhenium-Bis (Heteroaryl) Complexes, And Methods Of Use Thereof | SLC7A5, RAB35, AADAT | FOLH1 184/4885ITGB3 1296/4885ITGA2B 3240/4885 |
| US-20250197869-A1 | Ribosome-Mediated Incorporation of Peptides and Peptidomimetics | NPEPPS, DNPEP, AARS1 | FOLH1 1573/4885ITGB3 3604/4885ITGA2B 3741/4885 |
| US-20250145577-A1 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POLB, SNRPB2, HNRNPA2B1 | FOLH1 565/4885ITGB3 2985/4885ITGA2B 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.